Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) have been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $37.1667.

TYRA has been the subject of a number of recent research reports. Jefferies Financial Group boosted their target price on Tyra Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, February 3rd. Wedbush lifted their price objective on Tyra Biosciences from $30.00 to $37.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. Barclays began coverage on shares of Tyra Biosciences in a research report on Tuesday, January 27th. They set an “overweight” rating on the stock. Piper Sandler lifted their price target on shares of Tyra Biosciences from $33.00 to $42.00 and gave the stock an “overweight” rating in a research report on Friday, January 23rd. Finally, William Blair assumed coverage on shares of Tyra Biosciences in a research note on Tuesday. They set an “outperform” rating for the company.

Tyra Biosciences Price Performance

TYRA stock opened at $31.41 on Wednesday. The company has a 50 day moving average price of $27.22 and a 200 day moving average price of $18.59. Tyra Biosciences has a fifty-two week low of $6.42 and a fifty-two week high of $32.44. The stock has a market capitalization of $1.68 billion, a PE ratio of -16.80 and a beta of 1.07.

Insider Activity at Tyra Biosciences

In other news, Director Robert J. More sold 10,000 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $25.00, for a total value of $250,000.00. Following the transaction, the director owned 3,823,425 shares of the company’s stock, valued at $95,585,625. This represents a 0.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 15.20% of the company’s stock.

Institutional Investors Weigh In On Tyra Biosciences

A number of institutional investors have recently made changes to their positions in TYRA. Federated Hermes Inc. increased its holdings in Tyra Biosciences by 586.3% in the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock valued at $30,000 after purchasing an additional 1,841 shares during the last quarter. Chung Wu Investment Group LLC acquired a new position in shares of Tyra Biosciences during the 4th quarter worth about $53,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Tyra Biosciences by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after acquiring an additional 534 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Tyra Biosciences by 14.5% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock valued at $126,000 after acquiring an additional 1,668 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Tyra Biosciences in the 3rd quarter valued at approximately $133,000. 84.14% of the stock is owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.